Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0370220180620020109
Yakhak Hoeji
2018 Volume.62 No. 2 p.109 ~ p.117
A retrospective study of enoxaparin dosing in cancer patients based on renal function in South Korea
Seo Byeol

Yang Young-Mo
Choi Eun-Joo
Abstract
It is vital to prevent and effectively treat venous thromboembolism (VTE) with low-molecular-weight heparins, such as enoxaparin, in a timely manner to decrease the risk of VTE-associated mortality and morbidity in cancer patients. The aim of this study was to determine the appropriateness of enoxaparin doses administered for VTE prophylaxis or treatment according to the renal function of cancer patients hospitalized at a tertiary hospital in South Korea. This study was retrospectively conducted with cancer patients who were hospitalized at a tertiary hospital in South Korea between September 2012 and August 2013. Data were collected through a retrospective chart review of electronic medical records. A total of 603 cancer patients were included. Among 564 patients who received enoxaparin for VTE prophylaxis, 562 (99.7%) had not been overdosed (mean percent error [MPE] ¡Â 0) and 2 (0.3%) had been overdosed (MPE £¾ 0). Two hundred and twenty (39.0%) patients received appropriate doses of enoxaparin whereas 344 (61.0%) patients received inappropriate doses. Of the 344 patients who received inappropriate doses, all but 3 patients had been underdosed. In addition, among those who received enoxaparin for VTE treatment, 27 (75.0%) patients had not been overdosed (MPE ¡Â 0), whereas 9 (25.0%) patients had been overdosed (MPE £¾ 0). The majority of cancer patients in this study had not been overdosed with enoxaparin, but according to the evaluation based on predefined enoxaparin regimens, it was found that more than half of patients had received an inappropriate dose of enoxaparin.
KEYWORD
venous thromboembolism, low-molecular-weight heparin, enoxaparin, cancer, dose appropriateness, renal function
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI)